Navigation Links
Personalized Medicine Makes Significant Headway Following the Rapid Evolution of U.S. Molecular Diagnostics Market, Finds Frost & Sullivan

MOUNTAIN VIEW, Calif., May 5 /PRNewswire/ -- As early diagnosis of cancer is critical for faster cure, longer survival, and better quality of life for patients, better access to diagnostics is the uppermost priority for primary care. Innovative molecular technologies have generated a wave of cancer diagnostics developed by dynamic new market entrants. These efforts will go a long way in addressing the unmet needs in the early diagnosis of cancer.


Biomarker development is a major area of focus of the FDA-driven Critical Path Initiative. The biomarker development initiative will streamline the clinical trials process and ensure the development of diagnostics, targeted therapeutics, and relevant dosage regimens. Recent changes initiated by the European Medicines Agency (EMEA) in Europe are expected to have a spillover effect on the U.S. cancer molecular diagnostics (CMD) market and fuel growth in the companion diagnostics segment.

New analysis from Frost & Sullivan (, U.S. Cancer Molecular Diagnostics Markets, finds that this market earned revenues of over $270.1 million in 2007 and estimates this to reach $1.83 billion by 2014.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, please send an e-mail to Christina Alfaro, Corporate Communications, at, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

"The development of companion diagnostics is a game-changing phenomenon, which will impact the structure and dynamics of the pharmaceutical and biotechnology industry in the near future," advises Frost & Sullivan Senior Analyst Dr. Sudeep Basu. "Companion diagnostics will drive M&A activity and strategic partnerships in this market, in addition to encouraging a systems biology approach in attacking pathways as opposed to single targets."

The National Institute of Health-National Cancer Institute (NIH-NCI) programs, the FDA's Critical Path Initiative, and the availability of advanced tools have also speeded up market momentum. The Oncology Biomarkers Qualification Initiative (OBQI) program marshals public and private support to collaborate and develop the new rules of the game.

Considering the obvious benefits offered by this method and the lack of any deleterious effect observed with the testing, the likelihood of FDA granting approval for this method is high.

The flux in the regulatory environment surrounding the U.S. CMD market poses a major challenge to companies operating in this domain. Frequent adjustments to changing time lines and interim guidelines have proved to be an impediment for new entrants attempting to introduce novel tests to market.

"While FDA approval is no guarantee of market success, it surely helps the process," adds Dr. Basu. "FDA approval is based on a host of factors, and importantly, is an approval of the high levels of clinical relevance of the test, and low levels of risk which stems from the significant clinical studies carried out by the company for validating the diagnostic assay."

Besides adjusting to the ever-changing regulatory environment, participants must skillfully navigate the reimbursement space to ensure that growth continues on an upward trajectory.

A dual-pronged strategy -- bringing products to market through the Clinical Laboratory Improvement Amendments (CLIA) route and gaining early market dominance as well as going through the FDA process -- must be devised to tackle the regulatory and reimbursement barriers and achieve the speedy commercialization of molecular diagnostic tests.

This two-pronged approach will promote overall market visibility. It also ratchets up the awareness quotient among physicians. This serves to increase the overall branding and visibility of the test in the market. In order to interact smoothly with reimbursement agencies and convince them, U.S. CMD companies must accomplish insightful pharmacoeconomic analysis to display the value proposition of CMD.

U.S. Cancer Molecular Diagnostics Markets is part of the Drug Discovery and Clinical Diagnostics Growth Partnership Service program, which also includes research in the following markets: U.S. molecular diagnostics markets for emerging infectious disease tests, U.S. flow cytometry markets, and U.S. reference laboratory markets. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit

U.S. Cancer Molecular Diagnostics Markets


    Christina Alfaro
    Corporate Communications - North America
    P: 210.247.3830
    F: 210.348.1003

SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Biodesix Advances the Field of Personalized Medicine With the Launch of VeriStrat(R)
2. Personalized Medicine for Mental Illness on the Horizon
3. Mayo Clinic and Microsoft Deliver a Powerful and Personalized Consumer Solution for Managing Health
4. Ocean Cosmetic Medicine of Santa Monica Has Created Something New: Personalized Boutique Style Aesthetic Treatments
5. Frost & Sullivan Recognizes CRi for Innovations Leading to Personalized Medicine
6. Chicago-area ASBS Bariatric Surgery Center of Excellence Provides Personalized Care Like No Other Weight-Loss Surgery Program
7. Personalized genome sequencing reveals coding error in gene for inherited pancreatic cancer
8. Adena Shoulder Surgeon Blends Innovative Techniques with Personalized Patient Care
9. Investing in personalized medicine will benefit Canada
10. UCLA scientists develop crystal ball for personalized cancer treatment
11. One Million Americans Now Receive Personalized FDA Drug Safety Alerts Through
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... ... have developed valuable new strategies for enrolling and serving insurance consumers who do ... obtain health insurance and pay monthly premiums. In “Health Plan Engagement Strategies: The ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... smoke-free communities, and the Florida Apartment Association (FAA) has partnered with the Florida ... communities meet the demand. , The FAA Smoke-Free Multifamily Housing Program launched ...
(Date:10/13/2015)... ... 13, 2015 , ... Just under three months ago, eMarketing Concepts ... promotion – effectively offering all of their services for just a buck in the ... flooded with phone calls from interested buyers. As a genuine one-stop-shop for internet marketing, ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... a new PDF automation tool to batch conversions of CAD drawings, plans, ... 100% document fidelity. , CADConverter eliminates the complexity requirement of specialized applications to ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... The Bill ... in San Diego, also offering expert reconstruction and flood remediation services. Family-owned and operated ... They have been named the Best San Diego plumber two years in a row ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... Ga. , Oct. 12, 2015  MiMedx Group, ... company utilizing human amniotic tissue and patent-protected processes to ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and ... revenue results for the third quarter of 2015, its ... the Company has secured a $50 million Senior Secured ...
(Date:10/12/2015)... -- This study focuses on China,s ... past decades, the industry has been growing at a fast ... consumer consumptions in China have transformed ... China is one of the world,s major producers ... the world, China is the world,s ...
(Date:10/12/2015)... SACRAMENTO, Calif. , Oct. 12, 2015  In ... month in the Journal of Neurology, Neurosurgery, and Psychiatry, ... to reduce brain atrophy and cognitive decline in patients ... --> --> IVIG, extracted ... contains antibodies to amyloid, an abnormal brain protein found ...
Breaking Medicine Technology: